KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) EBT (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed EBT for 16 consecutive years, with -$100.8 million as the latest value for Q4 2025.

  • On a quarterly basis, EBT fell 156.59% to -$100.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $466.9 million, a 16.2% decrease, with the full-year FY2025 number at $466.9 million, down 16.2% from a year prior.
  • EBT was -$100.8 million for Q4 2025 at Halozyme Therapeutics, down from $219.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $219.0 million in Q3 2025 to a low of -$100.8 million in Q4 2025.
  • A 5-year average of $93.5 million and a median of $92.3 million in 2021 define the central range for EBT.
  • Peak YoY movement for EBT: soared 561.03% in 2021, then plummeted 156.59% in 2025.
  • Halozyme Therapeutics' EBT stood at $54.8 million in 2021, then increased by 29.16% to $70.8 million in 2022, then skyrocketed by 42.92% to $101.2 million in 2023, then surged by 76.14% to $178.2 million in 2024, then tumbled by 156.59% to -$100.8 million in 2025.
  • Per Business Quant, the three most recent readings for HALO's EBT are -$100.8 million (Q4 2025), $219.0 million (Q3 2025), and $204.9 million (Q2 2025).